Latham Advises GRAIL on Investment and Strategic Collaboration With Samsung and Separate PIPE Financing With a Combined Value of US$435 Million

Latham & Watkins advised GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, in a strategic collaboration with Samsung C&T (SCT) and Samsung Electronics (SEC) to bring GRAIL’s GalleriⓇ multi-cancer early detection (MCED) test to key Asian markets. In connection with the strategic collaboration, SCT and SEC agreed to invest US$110 million into GRAIL at a price of US$70.05 per share of common stock. The firm also advised GRAIL in its US$325 million private placement financing pursuant to a securities purchase agreement with new and existing institutional investors.

The Latham & Watkins LLP team who advised GRAIL on these transactions was led by Los Angeles partner Alex Voxman and Orange County/ Bay Area partner Ross McAloon, with associates Raul Gonzalez-Casarrubias and Edwin Gonzalez. Advice was also provided on collaboration, and intellectual property matters by San Diego partner Steve Chinowsky and counsel Robert Yeh; on US regulatory matters by Washington, D.C. partner James Barker and counsel Catherine Hein; on FDA regulatory matters by Washington, D.C. partner Liz Richards; and on tax matters by Los Angeles partner Pardis Zomorodi, Houston partner Jared Grimley and counsel William Kessler.